YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Alvotech (NASDAQ:ALVO) ranks among the oversold European stocks to buy. On March 19, Alvotech (NASDAQ:ALVO) revealed its full-year and Q4 2025 earnings results, delivering revenues of $593 million for the year, representing a 21% year-over…
Alvotech REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), incorporating by refer…
Alvotech REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the investor relations section of Alvotech’s website at: https://investors.alvotech…
Strong earnings weren't enough to please Alvotech's (NASDAQ:ALVO) shareholders over the last week. We did some digging and found some underlying numbers that are worrying. AI is about to change healthcare. These 20 stocks are working on ev…
Alvotech recently reported full-year 2025 results, swinging to net income of US$27.92 million from a prior-year net loss of US$231.86 million, alongside updates on FDA feedback, global biosimilar launches, and new commercialization agreeme…
Alvotech logo Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem Alvotech (NASDAQ:ALVO) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline progress on commercial launches, manufacturing…
Alvotech REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights Asupplemental long‑form earnings release providing additional operational details and busin…
Alvotech Asupplemental long‑form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental document is pro…
This article first appeared on GuruFocus. Alvotech (NASDAQ:ALVO) is set to release its Q4 2025 earnings on Mar 19, 2026. The consensus estimate for Q4 2025 revenue is $0.16 billion, and the earnings are expected to come in at -$0.20 per sh…
This article first appeared on GuruFocus. Alvotech (NASDAQ:ALVO) is set to release its Q4 2025 earnings on March 18, 2026. The consensus estimate for Q4 2025 revenue is $0.16 billion, and the earnings are expected to come in at -$0.20 per…
Alvotech Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the same perio…
Alvotech REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of…
In early November 2025, Alvotech announced that the U.S. FDA had issued a complete response letter for its Biologics License Application for AVT05, a biosimilar to Simponi, citing deficiencies from a July inspection at its Reykjavik manufa…
Wondering if Alvotech stock could be a hidden value opportunity or if all the recent volatility has you looking for answers? You’re in the right place to cut through the noise and get a clear perspective on what the numbers could mean for…
Alvotech’s consensus analyst price target has recently been revised down from $17.50 to $16.10 per share, following regulatory developments impacting the company’s biosimilar programs. This adjustment comes as the market reacts to the late…
Alvotech REYKJAVIK, Iceland and LONDON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Ho…
Market forces rained on the parade of Alvotech (NASDAQ:ALVO) shareholders today, when the analysts downgraded their forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the busines…
Alvotech REYKJAVIK, Iceland, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will re…
Alvotech (NasdaqGM:ALVO) shares have dipped over the past month, with the stock seeing an 8% slide. Investors may be weighing recent company performance and broader biotech sentiment as they consider Alvotech's value and future direction.…
Alvotech REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S.…
Alvotech Trisha DurantTrisha Durant, Senior Vice President, Global Business Development for Alvotech Harshika SarbajnaHarshika Sarbajna, Senior Vice President Commercial, North America for Alvotech Agne PaskoAgne Pasko, Vice President Head…
Advanz Pharma and Alvotech recently announced that the European Medicines Agency accepted a Marketing Authorization Application for AVT23, a proposed biosimilar to Xolair® (omalizumab), aimed at expanding options for severe allergic asthma…
Kashiv Biosciences has submitted its Biologics License Applications (BLA) for ADL-018 as a biosimilar to reference product XOLAIR® (omalizumab) to the U.S. Food and Drug Administration (FDA) The Marketing Authorization Application (MAA) fo…
Alvotech LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Eu…
Alvotech (NasdaqGM:ALVO) has caught some attention in the biotech space recently, especially given its stock movement over the past month. With a 3% increase in that period, investors are wondering what is behind the shift. See our latest…
In September 2025, Alvotech and its partners announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued positive recommendations for AVT03 (a biosimilar to Prolia and Xgeva) and Gobivaz (a biosimil…
Alvotech REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicine…
Alvotech REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma H…
Alvotech REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its comm…
Alvotech REYKJAVIK, Iceland, June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan S…
After announcing healthy earnings, Alvotech's (NASDAQ:ALVO) stock rose over the last week. Despite the strong profit numbers, we believe that there are some deeper issues which investors should look into. AI is about to change healthcare.…
Alvotech Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD) Approval is based on comprehensive…
Alvotech REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined t…
Explore Alvotech's Fair Values from the Community and select yours Alvotech (NASDAQ:ALVO) Second Quarter 2025 Results Key Financial Results Revenue: US$173.3m (down 13% from 2Q 2024). Net income: US$32.0m (down 51% from 2Q 2024). Profit ma…
Alvotech Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flows Continued expansion of commercial partnerships for pipeline assets Alvotech listed…
Alvotech REYKJAVIK, Iceland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will re…